Alterity Therapeutics: The race against Multiple System Atrophy

Multiple System Atrophy progresses faster than Parkinson's, attacks multiple systems at once, and takes an average of seven doctors before patients receive the correct diagnosis. There is currently no approved treatment.

On this episode of Vantage Point Podcast, we sit down with David Stamler (CEO) and Daniel Claassen (CMO) of Alterity Therapeutics to discuss their drug candidate ATH434, phase two results showing nearly 50% reduction in disease progression rate, and the path to a phase three trial.

We also cover Alterity's orphan drug and fast track FDA designations, upcoming phase three study design discussions, and the drug's potential beyond MSA - including Parkinson's and Friedreich's Ataxia.